Accordingly, the results of the present study further suggested that p-Akt and SKP2 are both important pharmacogenomic markers that can be used to predict the sensitivity of breast cancer cells to curcumin and that SKP2 silencing and p-Akt inhibition may be potent therapeutic alternatives that can be used in combination with curcumin to treat different breast cancer subtypes. This evidence concerns the gene SKP2 and breast cancer.